African swine fever (ASF) is currently the major concern of the global swine industry, as a consequence of which a reconsideration of the containment and prevention measures taken to date is urgently required. A great interest in developing an effective and safe vaccine against ASF virus (ASFV) infection has, therefore, recently appeared. The objective of the present study is to test an inactivated ASFV preparation under a vaccination strategy that has not previously been tested in order to improve its protective effect. The following have been considered: (i) virus inactivation by using a low binary ethyleneimine (BEI) concentration at a low temperature, (ii) the use of new and strong adjuvants; (iii) the use of very high doses (6 × 109 haemadsorption in 50% of infected cultures (HAD50)), and (iv) simultaneous double inoculation by two different routes of administration: intradermal and intramuscular. Five groups of pigs were, therefore, inoculated with BEI- Pol16/DP/OUT21 in different adjuvant formulations, twice with a 4-week interval. Six weeks later, all groups were intramuscularly challenged with 10 HAD50 of the virulent Pol16/DP/OUT21 ASFV isolate. All the animals had clinical signs and pathological findings consistent with ASF. This lack of effectiveness supports the claim that an inactivated virus strategy may not be a viable vaccine option with which to fight ASF.
African swine fever (ASF) is a viral disease of domestic and wild suids for which there is currently no vaccine or treatment available. The recent spread of ASF virus (ASFV) through Europe and Asia is causing enormous economic and animal losses. Unfortunately, the measures taken so far are insufficient and an effective vaccine against ASFV needs to be urgently developed. We hypothesized that immunization with a cocktail of thirty-five rationally selected antigens would improve the protective efficacy of subunit vaccine prototypes given that the combination of fewer immunogenic antigens (between 2 and 22) has failed to elicit protective efficacy. To this end, immunogenicity and efficacy of thirty-five adenovirus-vectored ASFV antigens were evaluated in wild boar. The treated animals were divided into different groups to test the use of BioMize adjuvant and different inoculation strategies. Forty-eight days after priming, the nine treated and two control wild boar were challenged with the virulent ASFV Arm07 isolate. All animals showed clinical signs and pathological findings consistent with ASF. This lack of protection is in line with other studies with subunit vaccine prototypes, demonstrating that there is still much room for improvement to obtain an effective subunit ASFV vaccine.
African swine fever (ASF) is a notifiable disease that in recent years has spread remarkably in Europe and Asia. Eurasian wild boar (Sus scrofa) plays a key role in the maintenance and spread of the pathogen. Here we examined gross pathology of infection in wild boar with a highly virulent, hemadsorbing genotype II ASF virus (ASFV) strain. To this end, six wild boars were intramuscularly inoculated with the 10 HAD50 Arm07 ASFV strain, and 11 wild boars were allowed to come into direct contact with the inoculated animals. No animals survived the infection. Clinical course, gross pathological findings and viral genome quantification by PCR in tissues did not differ between intramuscularly inoculated or contact-infected animals. Postmortem analysis showed enlargement of liver and spleen; serosanguinous effusion in body cavities; and multiple hemorrhages in lungs, endocardium, brain, kidneys, urinary bladder, pancreas, and alimentary system. These results provide detailed insights into the gross pathology of wild boar infected with a highly virulent genotype II ASFV strain. From a didactic point of view, this detailed clinical course and macroscopic description may be essential for early postmortem detection of outbreaks in wild boar in the field and contribute to disease surveillance and prevention efforts.
Since the reappearance of African swine fever virus (ASFV), the disease has spread in an unprecedented animal pandemic in Eurasia. ASF currently constitutes the greatest global problem for the swine industry. The wild boar (Sus scrofa) in which the pathogen has established wild self-sustaining cycles, is a key reservoir for ASFV, signifying that there is an urgent need to develop an effective vaccine against this virus. Current scientific debate addresses whether live attenuated vaccines (LAVs), which have shown promising results in cross-protection of susceptible hosts, may be feasible for vaccinations carried out owing to safety concerns. The objective of this study was, therefore, to compare the ASFV shedding in wild boar infected with virulent and attenuated (LAV) isolates. Different shedding routes (oral fluid and feces) and viremia rates were characterized in wild boar inoculated with Lv17/WB/Rie1 isolate (n = 12) when compared to those inoculated with the virulent Armenia07 isolate (n = 17). In general, fewer animals infected with the Lv17/WB/Rie1 isolate tested positive for ASFV in blood, oral fluid, and feces in comparison to animals infected with the virulent Armenia07 isolate. The shedding patterns were characterized in order to understand the transmission dynamics. This knowledge will help evaluate the shedding of new LAV candidates in wild boar populations, including the comparison with gene deletion mutant LAVs, whose current results are promising.
1 January 2025 in Transboundary and Emerging Diseases
Although several biosecurity and control measures are currently in place to mitigate the African swine fever (ASF) epidemic, vaccination is being explored as a potential long‐term strategy. However, standardized guidelines for evaluating the safety and efficacy of ASF vaccines are not yet fully established. Understanding infection dynamics in wild boar is crucial, as they play a key role in the spread and persistence of the virus. This work aims to provide comprehensive information on viral distribution through immunohistochemical analysis (p72) with histopathologic assessment in wild boar. The study design comprises animals: (i) intramuscular infected with the high‐virulence genotype II isolate Arm07 (highly virulent isolate [HVI]; n = 6); (ii) orally vaccinated with the low virulence isolate Lv17/WB/Rie1‐ Δ CD (low virulent isolate [LVI]; n = 6); and (iii) orally vaccinated with Lv17/WB/Rie1‐ Δ CD, either with a single dose (LVI‐HVI1; n = 6) or repeated doses (LVI‐HVI2; n = 6), followed by intramuscular challenge with Arm07. Clinical monitoring, viral load quantification in blood and tissues via real‐time quantitative PCR, and virus viability in tissue cultures using peripheral blood mononuclear cells were performed. HVI animals had hemorrhagic and inflammatory lesions, along with generalized lymphoid depletion, correlated with widespread viral dissemination. LVI animals rarely showed mild lymphoid depletion of the lymph nodes; minimal immunostaining was observed in macrophages of the tonsils and lymph nodes, typically restricted to the oral entry point. A few LVI–HVI1 cases had infected resident sinus macrophages related to necrotic lesions at tonsils and lymph nodes, preventing the virus from disseminating to vital organs. No viral immunostaining or associated histopathologic lesions were observed in LVI–HVI2 animals, indicating that revaccination enhances safety against virulent challenges. Observed changes following vaccination do not reflect chronic infection but rather a transient one, followed by lymphoid system recovery. Immunohistochemical and histological evaluation has proven valuable in advancing our understanding of ASF pathogenesis in wild boar, contributing to improved vaccination safety and disease management strategies.
African swine fever (ASF) is a highly contagious and lethal hemorrhagic disease affecting domestic pigs and wild boar, with serious consequences for animal health, the swine industry, and socio-economic stability. Given the lack of effective treatments and the limited success of conventional control measures, live attenuated vaccines (LAVs) have emerged as the most promising option, particularly for oral administration in free-ranging wild boar. The naturally attenuated genotype I isolate NH/P68 has shown protective potential in domestic pigs but retains residual virulence and persistence risks. To increase attenuation and facilitate large-scale production, the isolate was adapted to the MA104 continuous cell line. In this study, we assessed the safety and efficacy of NH/P68-MA104 in wild boar using an oral prime-boost immunization protocol (a primary dose of 10⁴ TCID₅₀/mL followed by two booster doses of 10⁵ TCID₅₀/mL), followed by a challenge with 10 HAD₅₀/mL of the virulent genotype II Armenia07 (Arm07) isolate. Oral administration of NH/P68-MA104 was safe, with no adverse effects observed throughout the vaccination period. Only one animal developed transient viremia, which was accompanied by clinical signs and a detectable antibody response. Two additional animals showed mild viremia, while the remaining animals displayed no evidence of infection or seroconversion before the challenge. After the challenge, vaccinated wild boar were not protected: all animals developed fever, viremia, and clinical signs consistent with acute ASF and succumbed at 14 ± 3 days post-challenge (dpc), comparable to in-contact and intramuscularly (IM) infected controls. These results demonstrate that oral immunization of wild boar with NH/P68-MA104 is safe but ineffective under the tested conditions. Continued research is needed to refine vaccine candidates and delivery strategies to achieve effective immunization of wild boar.